2 results match your criteria: "Atlanta (B.P.V.); and Johns Hopkins Hospital[Affiliation]"
Omalizumab for the Treatment of Multiple Food Allergies.
N Engl J Med
March 2024
From the Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore (R.A.W., J.D., K.M.), and the National Institutes of Health (National Institutes of Allergy and Infectious Diseases), Bethesda (A.T., A.K.R.S., M.V., S.D.H., E.B., J.P., L.M.W.) - both in Maryland; the Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York (S.H.S., J.W., M.G.); the Division of Pediatric Allergy and Immunology and Food Allergy Center, Massachusetts General Hospital, Boston (W.G.S., D.P.); the University of North Carolina School of Medicine (E.H.K., C.A.K., M.K.) and Rho (A.C., C.M.H., N.H.R., N.Y.) - both in Chapel Hill; the University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock (S.M.J., A.M.S.); National Jewish Health, Denver (D.Y.M.L., B.J.L.); Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta (B.P.V., T.L.); the Department of Pediatrics, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas (J.A.B., C.P.); the Division of Allergy and Immunology, Department of Pediatrics at Perelman School of Medicine at University of Pennsylvania, Philadelphia (J.M.S., T.B.-W.); Genentech-Roche, South San Francisco (A.I., J.O.), and Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Palo Alto (S.B.S., A.L., R.S.C.) - both in California; and Novartis Pharmaceuticals, East Hanover, NJ (M.L.-S., A.U.).
Article Synopsis
- A clinical trial tested the effectiveness and safety of omalizumab, an anti-IgE antibody, for treating multiple food allergies in individuals aged 1 to 55, primarily focusing on its ability to allow safe consumption of peanuts and other allergic foods.
- Out of 462 people screened, 177 children and adolescents completed the study, with 67% of those on omalizumab successfully consuming 600 mg of peanut protein without severe reactions, compared to only 7% of the placebo group.
- The results showed similar success rates for other allergenic foods (cashew, milk, and egg), with overall safety profiles being comparable, though more injection-site reactions were reported in those receiving omalizumab.
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
N Engl J Med
May 2023
From the Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora (M.G., D.M.F.); the Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford (S.B.S.), the University of California, San Francisco, San Francisco (M.J.D.), the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (M.G.-L.), the University of California, San Diego, La Jolla (S.L.), and Rady Children's Hospital San Diego, San Diego (S.L.) - all in California; the Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York (J.W., H.A.S.); the Department of Immunology, Perth Children's Hospital, and Telethon Kids Institute, Nedlands, WA (M.O.), Westmead Children's Hospital, Westmead, NSW (L.S.F., D.E.C.), Queensland Children's Hospital, University of Queensland, South Brisbane (J.P.), Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC (K.P.P.), Women's and Children's Hospital, North Adelaide, SA (P.Q.), and Sydney Children's Hospital, Randwick, NSW (B.W.) - all in Australia; Guy's and St. Thomas' NHS Foundation Trust (G.T.), and the National Heart and Lung Institute, Imperial College London (P.J.T.), London, the Lydia Becker Institute of Immunology and Inflammation, University of Manchester and Royal Manchester Children's Hospital, Manchester (P.D.A.), University Hospital Southampton NHS Foundation Trust, Southampton (M.E.-L.), and Sheffield Children's NHS Foundation Trust, Sheffield (N.J.) - all in the United Kingdom; the Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill (E.H.K., A.W.B.); UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh (D.A., T.D.G.); Baylor College of Medicine, Houston (S.A.), UT Southwestern Medical Center and Children's Medical Center, Dallas (C.P.), and Dell Medical School at the University of Texas, Dell Children's Medical Center of Central Texas, Austin (P.V.) - all in Texas; Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands (N.A.); Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal (P.B.), British Columbia Children's Hospital, University of British Columbia, Vancouver (E.S.C.), the Translational Medicine Program, Research Institute, and the Department of Immunology (T.E.), and the Division of Immunology and Allergy, Department of Paediatrics (J.E.M.U.), Hospital for Sick Children, University of Toronto, Toronto - all in Canada; the Department of Children and Adolescent Medicine, Division of Pneumology, Allergology and Cystic Fibrosis, University Hospital Frankfurt, Goethe University, Frankfurt (K.B.), Philipps-Universität Marburg, Marburg (W.P.), and Universitätsklinikum Carl Gustav Carus, Dresden (C.V.) - all in Germany; Hôpitaux Pédiatriques de Nice CHU Lenval, Nice (T. Bourrier, L.G.-C.), Université de Lille, CHU Lille, Pediatric Pulmonology and Allergy Unit, Hôpital Jeanne de Flandre, Lille (A.D.), the Pediatric Allergy Unit, Children's Hospital, University Hospital of Nancy, and EA3450 Development, Adaptation and Handicap, Faculty of Medicine, University of Lorraine, Nancy (A.D.-C.), the Department of Pediatric Pulmonology and Allergy, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, and University of Paris Cité, Paris (G.L.), and DBV Technologies, Montrouge (K.J.B., D.E.C., T.D.G., R.R., A.P., H.T.B., T. Bois, H.A.S.) - all in France; Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia (T.B.-W.); University of Arizona Medical Center, Tucson (H.C.); University of Chicago (C.E.C.), Northwestern University Feinberg School of Medicine (M.M.), and Ann and Robert H. Lurie Children's Hospital of Chicago (M.M., J.A.P., R.G.R.) - all in Chicago; the University of Tennessee Health Science Center, Memphis (J.A.L.); Vanderbilt University Medical Center, Nashville (S.L.D., R.G.R.); Karl Landsteiner University of Health Sciences, Krems, and the Department of Pediatric and Adolescent Medicine, University Hospital St. Pölten, St. Pölten - both in Austria (T.E.); Paediatrics and Child Health and the INFANT Center (J.O.H.) and the HRB Clinical Research Facility and the INFANT Research Center (J.T.), University College Cork, Cork University Hospital, Cork, and Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin (J.O.H.) - both in Ireland; University of Arkansas for Medical Sciences and Arkansas Children's Hospital - both in Little Rock (S.M.J.); Cleveland Clinic, Cleveland (L.A.K.); the Division of Pulmonary, Allergy, and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis (K.M.K.); University of Rochester, Rochester, NY (J.L., K.T.); Seattle Allergy and Asthma Research Institute, Seattle (D.P.); University of Michigan, Ann Arbor (G.S.); Boston Children's Hospital, Boston (L.S.); Children's National Health System, Washington, DC (H.P.S.); Emory University, Atlanta (B.P.V.); and Johns Hopkins Hospital, Baltimore (R.A.W.).
Background: No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.
Methods: We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving children 1 to 3 years of age with peanut allergy confirmed by a double-blind, placebo-controlled food challenge. Patients who had an eliciting dose (the dose necessary to elicit an allergic reaction) of 300 mg or less of peanut protein were assigned in a 2:1 ratio to receive epicutaneous immunotherapy delivered by means of a peanut patch (intervention group) or to receive placebo administered daily for 12 months.